- Home
- RIGL vs ATXS Comparison
RIGL vs ATXS Comparison
Compare RIGL & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ATXS
- Stock Information
- Founded
- RIGL 1996
- ATXS 2008
- Country
- RIGL United States
- ATXS United States
- Employees
- RIGL N/A
- ATXS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- ATXS Health Care
- Exchange
- RIGL Nasdaq
- ATXS Nasdaq
- Market Cap
- RIGL 335.5M
- ATXS 401.2M
- IPO Year
- RIGL 2000
- ATXS 2015
- Fundamental
- Price
- RIGL $21.91
- ATXS $6.56
- Analyst Decision
- RIGL Buy
- ATXS Buy
- Analyst Count
- RIGL 5
- ATXS 6
- Target Price
- RIGL $36.40
- ATXS $32.00
- AVG Volume (30 Days)
- RIGL 182.1K
- ATXS 233.1K
- Earning Date
- RIGL 08-05-2025
- ATXS 08-11-2025
- Dividend Yield
- RIGL N/A
- ATXS N/A
- EPS Growth
- RIGL N/A
- ATXS N/A
- EPS
- RIGL 2.08
- ATXS N/A
- Revenue
- RIGL $203,077,000.00
- ATXS N/A
- Revenue This Year
- RIGL $14.41
- ATXS N/A
- Revenue Next Year
- RIGL $15.97
- ATXS N/A
- P/E Ratio
- RIGL $10.11
- ATXS N/A
- Revenue Growth
- RIGL 70.16
- ATXS N/A
- 52 Week Low
- RIGL $8.61
- ATXS $3.56
- 52 Week High
- RIGL $29.82
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- ATXS 55.85
- Support Level
- RIGL $19.51
- ATXS $6.31
- Resistance Level
- RIGL $21.41
- ATXS $7.34
- Average True Range (ATR)
- RIGL 0.88
- ATXS 0.36
- MACD
- RIGL 0.24
- ATXS -0.01
- Stochastic Oscillator
- RIGL 96.45
- ATXS 44.29
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.